ЕРЛЕРО

उत्पाद अवलोकन

About ЕРЛЕРО

ЕРЛЕРО is a prescription medication containing the active ingredient Erlotinib, a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. It works by blocking the epidermal growth factor receptor (EGFR) tyrosine kinase, thereby inhibiting tumor growth and metastasis.

Key Benefits & Uses

• Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
• Treatment of locally advanced or metastatic pancreatic cancer in patients with a history of gastrectomy and an activating mutation in the KRAS gene.
• ERLЕРО may be used in combination with other medications to treat NSCLC and pancreatic cancer.

Active Ingredient & Action

Erlotinib, the active ingredient in ЕРЛЕРО, works by selectively inhibiting the tyrosine kinase activity of the EGFR, which is involved in the regulation of cell growth and division. By blocking EGFR, Erlotinib prevents the proliferation of cancer cells and induces apoptosis (cell death).

Important Notes

ЕРЛЕРО is available in tablet form and should be taken orally once daily. It is essential to follow the recommended dosage and administration instructions provided by your healthcare provider. Common side effects of ЕРЛЕРО include rash, diarrhea, and fatigue. Patients with a history of interstitial lung disease or a history of radiation pneumonitis should use ЕРЛЕРО with caution. Consult your healthcare provider before taking ЕРЛЕРО if you have any underlying medical conditions or are taking other medications.